Over the course of 20 years, Dr. Zlokovic has demonstrated that damage to the blood-brain barrier and microcirculation has a key role in the development of a neurodegenerative process in diseases such as Alzheimer’s disease and related neurodegenerative disorders. Collectively, he proposed that vascular-mediated neurodegeneration may underlie cognitive decline. These discoveries are of exceptional importance to understanding pathogenesis of neurodegenerative disorders and dementias, including Alzheimer’s disease. Besides academic interests, Zlokovic is co-founder with Mr. Selim K. Zilkha of three biotechnology companies with a mission to develop new therapies for the aging and damaged brain, including: ZZ (Zilkha-Zlokovic) Alztech, which focuses on development of new therapeutics and diagnostics for Alzheimer’s disease and manufacturing of a recombinant lipoprotein receptor for Alzheimer’s disease treatment; ZZ (Zilkha-Zlokovic), Biotech, which focuses on manufacturing recombinant secon-generation analog of activated protein C for stroke; Socratech L.L.C., which focuses on vascular genes and drug screening in Alzheimer’s disease.